WSLCB - Executive Management Team (August 9, 2023) - Summary
The board heard about implementation of legislation and possible request bills; social equity applications; lab authority transfer; plus updates on medical endorsements and hiring.
The board heard about implementation of legislation and possible request bills; social equity applications; lab authority transfer; plus updates on medical endorsements and hiring.
WSLCB leaders introduced two concepts for 2024 request legislation, one for medical patients to contract with licensees; another to revise limits around cannabis retail advertising.
The intention of staff to replace CCRS with a traceability system was questioned by board members, who next learned about the new staff and portfolio for the in-house research office.
With DOE staff moving forward on cannabis lab accreditation rulemaking, they explained the expected timeline for draft rules and heard feedback about the costly implications for labs.
A congressional committee heard how lack of federal rulemaking on CBD and hemp products contributed to endangering consumers through sale of unsafe hemp-derived cannabinoid products.
A longtime employee was recognized, staff were working with the equity scoring vendor on acceptable documentation, and stakeholders wanted the agency to learn from past traceability efforts.
A new manager took over the Policy and Rules work at WSLCB and provided updates on a legislatively mandated cannabis project and a licensee survey for a rulemaking petition.
A campaign focused on reducing youth cannabis use and impaired driving was getting positive results according to the program manager who presented and answered questions.
Staff went through subjects discussed during the CANNRA external stakeholder meeting, plus updates on licensing, social equity, and interest in a new traceability system.
The board heard how an environmental pesticides investigation was nearing completion along with comments from the incoming agency director and plans for staff focus groups.